Effect of Aplidin in acute lymphoblastic leukaemia cells.
| Autor: | Erba, E., Serafini, M., Gaipa, G., Tognon, G., Marchini, S., Celli, N., Rotilio, D., Broggini, M., Jimeno, J., Faircloth, G. T., Biondi, A., D'Incalci, M. |
|---|---|
| Předmět: |
LEUKEMIA
CELL death GENETICS APOPTOSIS RNA metabolism CANCER cell culture PROTEINS RESEARCH B cells LYMPHOBLASTIC leukemia ENDOTHELIAL growth factors GROWTH factors RESEARCH methodology ANTINEOPLASTIC agents KARYOTYPES PROTEOLYTIC enzymes EVALUATION research LYMPHOKINES CELL cycle COMPARATIVE studies MASS spectrometry DOSE-effect relationship in pharmacology VASCULAR endothelial growth factors CONNECTIVE tissue cells PEPTIDES DRUG resistance in cancer cells PHARMACODYNAMICS |
| Zdroj: | British Journal of Cancer; 8/18/2003, Vol. 89 Issue 4, p763-773, 11p |
| Abstrakt: | The cytotoxic effect of Aplidin was investigated on fresh leukaemia cells derived from children with B-cell-precursor (BCP) acute lymphoblastic leukaemia (ALL) by using stromal-layer culture system and on four cell lines, ALL-PO, Reh, ALL/MIK and TOM-1, derived from patients with ALL with different molecular genetic abnormalities. In ALL cell lines Aplidin was cytotoxic at nanomolar concentrations. In the ALL cell lines the drug-induced cell death was clearly related to the induction of apoptosis and appeared to be p53-independent. Only in ALL-PO 20 nM Aplidin treatment caused a block of vascular endothelial growth factor (VEGF) secretion and downregulation of VEGF-mRNA, but Aplidin cytotoxicity does not seem to be related to VEGF inhibition since the sensitivity of ALL-PO cells to Aplidin is comparable to that observed for the other cells used. Aplidin induced a G(1) and a G(2) M block in ALL cell lines. In patient-derived leukaemia cells, Aplidin induced a strong cytotoxicity evidenced in a stroma-supported immunocytometric assay. Cells from children with genetic abnormalities such as t(9;22) and t(4;11) translocations, associated with an inferior treatment outcome, were sensitive to Aplidin to the same extent as that observed in other BCP-ALL cases. Aplidin exerted a strong cell killing effect (>88%) against primary culture cells from five relapsed ALL cases, at concentrations much lower than those reported to be achieved in plasma of patients receiving Aplidin at recommended doses. Taken together these data suggest that Aplidin could be a new anticancer drug to be investigated in ALL patients resistant to available therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|